<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00655538</url>
  </required_header>
  <id_info>
    <org_study_id>BC21144</org_study_id>
    <secondary_id>2007-003406-10</secondary_id>
    <nct_id>NCT00655538</nct_id>
  </id_info>
  <brief_title>A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patients</brief_title>
  <official_title>A Randomized, Placebo-controlled Study of the Safety, Tolerability and Effect on Endothelial Function, as Measured by Flow Mediated Dilatation, of RO4607381 in Patients With Coronary Heart Disease (CHD) or CHD Risk Equivalents.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This study will assess the safety, tolerability and efficacy of RO4607381 in patients with
      coronary heart disease (CHD) or CHD risk equivalents. Patients will be randomized to receive
      either RO4607381 600mg po daily or placebo po daily. Endothelial function will be measured by
      flow mediated dilatation and blood pressure monitoring will be assessed. The anticipated time
      on study treatment is up to 12 months, and the target sample size is up to 500 individuals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in % Flow Mediated Dilatation (FMD)</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Mean BP, Measured by BP Monitoring</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in % FMD</measure>
    <time_frame>baseline and 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in HDL-C, LDL-C, Total Cholesterol, Triglycerides, ApoA1, ApoB</measure>
    <time_frame>Baseline to 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CETP Activity</measure>
    <time_frame>Up to 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline of sP-Selectin, sE-Selectin, Soluble Intracellular Adhesion Molecule, Soluble Vascular Cell Molecule, Lipoprotein-associated phospholipaseA2s, Matrix Metalloproteinase-3, Matrix metalloproteinase9</measure>
    <time_frame>Baseline and 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean BP, Measured by BP Monitoring</measure>
    <time_frame>Up to 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change CETP Mass</measure>
    <time_frame>baseline to 36 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">476</enrollment>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>Dalcetrapib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>po daily for 36 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dalcetrapib</intervention_name>
    <description>600mg po daily for 36 weeks</description>
    <arm_group_label>Dalcetrapib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patients, 18-75 years of age;

          -  CHD or CHD risk equivalent;

          -  appropriately treated for accepted LDL-C level.

        Exclusion Criteria:

          -  treatment with drugs raising HDL-C (eg niacin, fibrates);

          -  uncontrolled hypertension;

          -  recent (within 3 months) clinically significant coronary events, transient ischemic
             attacks or cerebrovascular accident;

          -  severe anemia;

          -  poorly controlled diabetes.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Feldkirch</city>
        <zip>6800</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wuppertal</city>
        <zip>42117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pisa</city>
        <state>Toscana</state>
        <zip>56100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Breda</city>
        <zip>4811 SW</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eindhoven</city>
        <zip>5611 NJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goes</city>
        <zip>4462 RA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Groningen</city>
        <zip>9711 SG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hoorn</city>
        <zip>1625 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leiderdorp</city>
        <zip>2352 RA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nijmegen</city>
        <zip>6525 EC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rotterdam</city>
        <zip>3021 HC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Utrecht</city>
        <zip>3508 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Velp</city>
        <zip>6883 ES</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zoetermeer</city>
        <zip>2724 EK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lugano</city>
        <zip>6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>ZÃ¼rich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4XN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>March 28, 2008</study_first_submitted>
  <study_first_submitted_qc>April 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2008</study_first_posted>
  <results_first_submitted>July 17, 2019</results_first_submitted>
  <results_first_submitted_qc>December 13, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 2, 2020</results_first_posted>
  <last_update_submitted>December 13, 2019</last_update_submitted>
  <last_update_submitted_qc>December 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dalcetrapib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dalcetrapib</title>
          <description>dalcetrapib: 600mg po daily for 36 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo: po daily for 36 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="238"/>
                <participants group_id="P2" count="238"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="214"/>
                <participants group_id="P2" count="211"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dalcetrapib</title>
          <description>dalcetrapib: 600mg po daily for 36 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo: po daily for 36 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="232"/>
            <count group_id="B2" value="234"/>
            <count group_id="B3" value="466"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.3" spread="7.05"/>
                    <measurement group_id="B2" value="61.9" spread="7.92"/>
                    <measurement group_id="B3" value="62.1" spread="7.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="211"/>
                    <measurement group_id="B2" value="211"/>
                    <measurement group_id="B3" value="422"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in % Flow Mediated Dilatation (FMD)</title>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>10 subjects dropped before week 12</population>
        <group_list>
          <group group_id="O1">
            <title>Dalcetrapib</title>
            <description>dalcetrapib: 600mg po daily for 36 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: po daily for 36 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in % Flow Mediated Dilatation (FMD)</title>
          <population>10 subjects dropped before week 12</population>
          <units>%FMD</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="232"/>
                <count group_id="O2" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.13"/>
                    <measurement group_id="O2" value="0.32" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Mean BP, Measured by BP Monitoring</title>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>not all participants were tested</population>
        <group_list>
          <group group_id="O1">
            <title>Dalcetrapib</title>
            <description>dalcetrapib: 600mg po daily for 36 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: po daily for 36 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean BP, Measured by BP Monitoring</title>
          <population>not all participants were tested</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" spread="0.57"/>
                    <measurement group_id="O2" value="0.31" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in % FMD</title>
        <time_frame>baseline and 36 weeks</time_frame>
        <population>not all participants were tested</population>
        <group_list>
          <group group_id="O1">
            <title>Dalcetrapib</title>
            <description>dalcetrapib: 600mg po daily for 36 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: po daily for 36 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in % FMD</title>
          <population>not all participants were tested</population>
          <units>%FMD</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="232"/>
                <count group_id="O2" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.50" spread="6.27"/>
                    <measurement group_id="O2" value="20.13" spread="5.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in HDL-C, LDL-C, Total Cholesterol, Triglycerides, ApoA1, ApoB</title>
        <time_frame>Baseline to 36 weeks</time_frame>
        <population>not all participants were tested</population>
        <group_list>
          <group group_id="O1">
            <title>Dalcetrapib</title>
            <description>dalcetrapib: 600mg po daily for 36 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: po daily for 36 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in HDL-C, LDL-C, Total Cholesterol, Triglycerides, ApoA1, ApoB</title>
          <population>not all participants were tested</population>
          <units>Percent change in mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HDL-C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.70" spread="1.45"/>
                    <measurement group_id="O2" value="-0.14" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.43" spread="2.22"/>
                    <measurement group_id="O2" value="8.72" spread="2.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.66" spread="1.20"/>
                    <measurement group_id="O2" value="5.90" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.58" spread="2.66"/>
                    <measurement group_id="O2" value="11.62" spread="2.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ApoA1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.84" spread="0.97"/>
                    <measurement group_id="O2" value="2.61" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ApoB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.70" spread="1.23"/>
                    <measurement group_id="O2" value="1.98" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CETP Activity</title>
        <time_frame>Up to 36 weeks</time_frame>
        <population>not all participants were tested</population>
        <group_list>
          <group group_id="O1">
            <title>Dalcetrapib</title>
            <description>dalcetrapib: 600mg po daily for 36 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: po daily for 36 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>CETP Activity</title>
          <population>not all participants were tested</population>
          <units>Percent change pMOL/uL/hr</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48.66" spread="2.12"/>
                    <measurement group_id="O2" value="7.37" spread="2.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline of sP-Selectin, sE-Selectin, Soluble Intracellular Adhesion Molecule, Soluble Vascular Cell Molecule, Lipoprotein-associated phospholipaseA2s, Matrix Metalloproteinase-3, Matrix metalloproteinase9</title>
        <time_frame>Baseline and 36 weeks</time_frame>
        <population>not all participants were tested</population>
        <group_list>
          <group group_id="O1">
            <title>Dalcetrapib</title>
            <description>dalcetrapib: 600mg po daily for 36 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: po daily for 36 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline of sP-Selectin, sE-Selectin, Soluble Intracellular Adhesion Molecule, Soluble Vascular Cell Molecule, Lipoprotein-associated phospholipaseA2s, Matrix Metalloproteinase-3, Matrix metalloproteinase9</title>
          <population>not all participants were tested</population>
          <units>Percent change in ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>sP-Selectin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.83" spread="1.58"/>
                    <measurement group_id="O2" value="0.24" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sE-Selectin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.01" spread="1.95"/>
                    <measurement group_id="O2" value="6.08" spread="1.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Soluble intracellular adhesion molecule</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" spread="0.95"/>
                    <measurement group_id="O2" value="2.01" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Soluble vascular cell molecule</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.60" spread="0.79"/>
                    <measurement group_id="O2" value="1.86" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipoprotein-associated phospholipaseA2s</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.24" spread="3.34"/>
                    <measurement group_id="O2" value="5.80" spread="3.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Matrix metalloproteinase-3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.46" spread="2.12"/>
                    <measurement group_id="O2" value="3.44" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Matrix metalloproteinase9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.12" spread="10.97"/>
                    <measurement group_id="O2" value="20.36" spread="10.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean BP, Measured by BP Monitoring</title>
        <time_frame>Up to 36 weeks</time_frame>
        <population>not all participants were tested</population>
        <group_list>
          <group group_id="O1">
            <title>Dalcetrapib</title>
            <description>dalcetrapib: 600mg po daily for 36 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: po daily for 36 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean BP, Measured by BP Monitoring</title>
          <population>not all participants were tested</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.93" spread="0.60"/>
                    <measurement group_id="O2" value="1.17" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change CETP Mass</title>
        <time_frame>baseline to 36 weeks</time_frame>
        <population>not all participants were tested</population>
        <group_list>
          <group group_id="O1">
            <title>Dalcetrapib</title>
            <description>dalcetrapib: 600mg po daily for 36 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: po daily for 36 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change CETP Mass</title>
          <population>not all participants were tested</population>
          <units>Percent change in ug/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.19" spread="2.70"/>
                    <measurement group_id="O2" value="5.17" spread="2.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dalcetrapib</title>
          <description>dalcetrapib: 600mg po daily for 36 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: po daily for 36 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Atrial Fibrilation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Purexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Appendicitis Perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Postoperative Thoracic Procedure Complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral Disc Protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Lung Neoplasm Malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Migrane</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Transient Ischemic Attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Urethral Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign Prostatic Hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea Exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="112" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ryan Black</name_or_title>
      <organization>DalCor Pharmaceuticals</organization>
      <email>rblack@dalcorpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

